VX-993 was generally safe and well tolerated at all doses studied in the trial. The overall incidence of adverse events on VX-993 was similar to placebo. The majority of the AEs were mild or moderate ...

Fintel reports that on September 3, 2025, Raymond James initiated coverage of Vertex Pharmaceuticals (NasdaqGS:VRTX) with a Market Perform recommendation. Analyst Price Forecast Suggests 23.94% Upside ...

Disappointing trial results for VX-993 led to a sell-off of Vertex's stock recently. The company's financials remain strong, and sales were up 12% last quarter. Vertex has been broadening its pipeline ...

You can find the Vertex Watch Company tucked among the narrow cobbled streets, quaint boutiques and flower-decked pubs of London's Shepherd Market. It fits right in. Inside its Georgian townhouse HQ, ...

A federal judge upheld a Hampton Zoning Board decision to deny a 150-foot cell tower proposed by Vertex Towers. The judge ruled the board's decision was supported by substantial evidence, including a ...

This story appeared in Esquire's About Time newsletter. Get it free into your inbox every Sunday at 8am. Sign up here You can find the Vertex Watch Company tucked among the narrow cobbled streets, ...

Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators said they didn’t see a path forward for broad use of its pill in treating a ...

- In head-to-head clinical trials, ALYFTREK was non-inferior on ppFEV 1 and superior in reducing sweat chloride compared to TRIKAFTA - - Approximately 3,800 people in Canada are now eligible for ...

Zimislecel is an allogeneic stem cell–derived islet-cell therapy. Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed. We conducted a phase 1–2 study of zimislecel ...